The Clinical Trials of Mesenchymal Stromal Cells Therapy
| Autor: | Vahid Najafzadeh, Reza Shirazi, Shabnam Bakhshalizadeh, Safoura Izanlou, Arezoo Khoradmehr, Seyedeh Farzaneh Moniri, Mandana Baghban, Mohammad Reza Kouchakian, Iraj Nabipour, Neda Baghban, Amin Tamadon, Zahra Safaei |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
2019-20 coronavirus outbreak
Chemotactic Cytokines business.industry Mesenchymal stem cell Cell Cell Biology Review Article Bioinformatics RC31-1245 Clinical trial Cell therapy Heterogeneous population medicine.anatomical_structure Medicine business Internal medicine Molecular Biology Adult stem cell |
| Zdroj: | Stem Cells International Stem Cells International, Vol 2021 (2021) |
| ISSN: | 1687-9678 1687-966X |
| Popis: | Mesenchymal stromal cells (MSCs) are a heterogeneous population of adult stem cells, which are multipotent and possess the ability to differentiate/transdifferentiate into mesodermal and nonmesodermal cell lineages. MSCs display broad immunomodulatory properties since they are capable of secreting growth factors and chemotactic cytokines. Safety, accessibility, and isolation from patients without ethical concern make MSCs valuable sources for cell therapy approaches in autoimmune, inflammatory, and degenerative diseases. Many studies have been conducted on the application of MSCs as a new therapy, but it seems that a low percentage of them is related to clinical trials, especially completed clinical trials. Considering the importance of clinical trials to develop this type of therapy as a new treatment, the current paper is aimed at describing characteristics of MSCs and reviewing relevant clinical studies registered on the NIH database during 2016-2020 to discuss recent advances on MSC-based therapeutic approaches being used in different diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text